Targeted protein degradation (TPD) primarily degrades target proteins through the ubiquitin-proteasome and lysosome, and according to the specific mechanism of action, it can be further subdivided into nearly 10 different technical routes,Read More…
N 6-methyladenosine (m6A) methylation is the most abundant type of RNA modification, primarily catalyzed by the METTL3-METTL14 methyltransferase complex (MTC). This complex includes the core catalytic proteins METTL3 and METTL14, as wellRead More…
ROTAC technology has advantages such as targeting non-druggable targets, high catalytic activity, and overcoming drug resistance, making it a new strategy in drug development. Traditional Protein Degrader design and synthesis require aRead More…
When targeting harmful proteins that cause or spread disease, drugs usually block the protein’s active site, making it unable to function and causing severe damage. New strategies targeting these proteins may sendRead More…
In Alzheimer’s disease, fibrous tau pathology accumulates and spreads in the brain, leading to synaptic loss. Researchers studying mouse models have found that tau protein can spread from presynaptic to postsynaptic synapses,Read More…
Proteins with short lifespans control gene expression in cells and perform many crucial tasks, from aiding in brain connectivity to assisting the body in immune defense. These proteins are produced in theRead More…
In a new study, researchers from the University of Oxford, the University of Cambridge, and the Pirbright Institute in the UK have discovered a novel therapeutic approach to investigating how poxviruses evadeRead More…
The ubiquitin-proteasome system is one of the main pathways for cellular protein degradation. In recent years, methods for artificially degrading target proteins through UPS have been developed. Targeted protein degradation agents areRead More…
Introduction Various types of delivery systems, including organic/inorganic nanoparticles, small molecule targeting moieties, and antibodies, have been explored as carriers for Protein Degraders. These systems play a crucial role in addressing theRead More…
Preclinical evidence of Protein Degrader The breakthrough in Protein Degrader’s design paves the way for its early clinical trials. According to statistics, as of January 8, 2023, 18 kinds of Protein DegraderRead More…